Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64.5M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
17.3M
-
Shares change
-
-158K
-
Total reported value, excl. options
-
$118M
-
Value change
-
-$3.8M
-
Number of buys
-
21
-
Number of sells
-
-22
-
Price
-
$6.82
Significant Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q4 2021
56 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q4 2021.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.3M shares
of 64.5M outstanding shares and own 26.83% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (2.44M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.34M shares), Sofinnova Investments, Inc. (2.03M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.6M shares), Pivotal bioVenture Partners Investment Advisor LLC (1.59M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.01M shares), CHI Advisors LLC (892K shares), Rock Springs Capital Management LP (868K shares), BlackRock Inc. (837K shares), and FMR LLC (609K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.